Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $19.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price hoisted by stock analysts at Wells Fargo & Company from $18.00 to $19.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective indicates a potential upside of 12.13% from the stock’s previous close.

Several other brokerages also recently issued reports on RARE. Weiss Ratings reissued a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 6th. Evercore lowered Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price target for the company. in a research note on Thursday, September 3rd. Jefferies Financial Group dropped their price objective on shares of Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, September 3rd. Citigroup lifted their target price on Ultragenyx Pharmaceutical from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, September 18th. Finally, Cantor Fitzgerald upped their price target on shares of Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the company an “overweight” rating in a report on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $33.65.

Ultragenyx Pharmaceutical Trading Up 1.9%

Ultragenyx Pharmaceutical stock traded up $0.31 during trading on Wednesday, reaching $16.94. The company had a trading volume of 1,068,572 shares, compared to its average volume of 2,841,309. The firm’s 50-day simple moving average is $16.64 and its 200 day simple moving average is $22.81. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -2.89 and a beta of 0.37. Ultragenyx Pharmaceutical has a 52 week low of $12.73 and a 52 week high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The firm had revenue of $173.00 million during the quarter, compared to analysts’ expectations of $182.49 million. During the same quarter in the prior year, the business earned ($1.81) earnings per share. The firm’s revenue for the quarter was up 8.2% on a year-over-year basis. On average, analysts predict that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the sale, the chief financial officer owned 89,229 shares of the company’s stock, valued at approximately $1,362,526.83. This trade represents a 7.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 8,510 shares of company stock worth $127,561 in the last ninety days. 5.20% of the stock is owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. grew its holdings in shares of Ultragenyx Pharmaceutical by 295.4% during the third quarter. Assenagon Asset Management S.A. now owns 477,869 shares of the biopharmaceutical company’s stock valued at $7,182,000 after buying an additional 357,005 shares during the last quarter. BlackRock Inc. acquired a new stake in Ultragenyx Pharmaceutical during the second quarter worth about $355,746,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at approximately $6,397,000. Deutsche Bank AG purchased a new position in Ultragenyx Pharmaceutical in the second quarter valued at $5,503,000. Finally, Corient Private Wealth LP purchased a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at about $4,644,000. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reaffirmed its 2026 revenue and 2027 profitability guidance. It expects expense and workforce reductions to cut 2027 R&D spending by at least 50% compared with 2025. Ultragenyx third-quarter results and outlook
• Positive Sentiment: The company said it has agreements to sell two Priority Review Vouchers for a combined $413 million, providing a substantial source of cash. FDA approvals of GENGLYCOS and FAYUVI were also announced during the quarter. Ultragenyx third-quarter results and outlook
• Neutral Sentiment: Revenue rose 8.2% year over year to $173 million, including $109 million from CRYSVITA and $30 million from DOJOLVI. The quarterly loss narrowed to $1.16 per share from $1.81 a year earlier. Ultragenyx third-quarter earnings results
• Negative Sentiment: Despite year-over-year improvement, the $1.16 per-share loss was slightly wider than analysts’ roughly $1.10–$1.15 expected loss, and revenue of $173 million fell short of the $182.5 million consensus estimate. Ultragenyx Q3 loss and revenue results

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.